With the caveat that cross-trial comparisons can be unreliable, zasocitinib appears to have an advantage over Sotyktu. BMS reported PASI 90 rates of 32% to 42% and PASI 100 rates of 10% to 14% in its ...
After collecting an FDA approval earlier this year for local pancreatic cancer, Novocure is putting forward positive clinical ...
Excellergy has been snapped up by the Swiss pharma only five months after emerging with $70 million in funds. The Palo Alto, ...
Incubate Founder and Executive Director John Stanford spent a busy day on Capitol Hill this week making the case that the ...
Merck and Terns Pharmaceuticals have agreed to a $6.7 billion all-cash buyout that delivers a prized leukemia asset to the ...
Wave Life Sciences linked its obesity drug candidate to a 1% dip in body weight after six months, leading investors to drive ...
Whatever the reasons, AstraZeneca has emerged as the first IL-33 player to show consistent efficacy. Sanofi and Regeneron ...
Philips has secured an FDA clearance for its artificial intelligence program that tracks and guides the placement of a ...
China’s BrightGene has served up a slice of early-stage data to remind everyone it has a horse in the oral obesity race. | ...
Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
Sarepta Therapeutics has shared initial clinical data on two siRNA candidates, delivering an early look at the wisdom of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results